Identification of Out-of-Trend Stability Results

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-02-2003
Volume 27
Issue 4

Representatives from PhRMA member companies discuss the growing concern about out-of-trend stability data, including possible statistical approaches and the implementation challenges to identifying OOT results.

External Link - article-52982.pdf

Articles in this issue
Outsourcing Outlook
April 2003
Identification of Out-of-Trend Stability Results
The Relative Densisties of Pharmaceutical Powders, Blends, Dry Granulations, and Immediate-Release Tablets
Overhauling Compliance and GMPs
A Film Approach for the Stabilization of Gelatin Preparations Against Cross-Linking
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Related Content
INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

Patrick Lavery;Feliza Mirasol
April 1st 2025
Article

William Wainwright, business development manager at Iwata Label USA, discusses the practical security benefits of functional labels at INTERPHEX 2025.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Culture Biosciences Opens INTERPHEX 2025 with Launch of Cloud-Integrated Mobile Bioreactor

Patrick Lavery
April 1st 2025
Article

The company said the Stratyx 250 is the first bioreactor of its kind to offer biotech companies a combination of automation, remote process control, and flexibility.

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Facing the Latest Patent Cliff

Mike Hennessy Jr.
April 1st 2025
Article

Over the course of the next five years, the bio/pharma industry is expected to see the patents of multiple blockbuster drugs expire, impacting some key industry players.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.